Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older

Trial Identifier: VBT00002
Sponsor: Sanofi
Start Date: November 2024
Primary Completion Date: April 2026
Study Completion Date: April 2026
Condition: Influenza Immunisation; COVID-19 Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
UNITED STATES, Arizona PHOENIX, Arizona, UNITED STATES, 85020
UNITED STATES, California CERRITOS, California, UNITED STATES, 90704
UNITED STATES, California VISTA, California, UNITED STATES, 92083
UNITED STATES, Florida MELBOURNE, Florida, UNITED STATES, 32934
UNITED STATES, Florida ORLANDO, Florida, UNITED STATES, 32806
UNITED STATES, Illinois PEORIA, Illinois, UNITED STATES, 61614
UNITED STATES, Indiana EVANSVILLE, Indiana, UNITED STATES, 47714
UNITED STATES, Massachusetts MALDEN, Massachusetts, UNITED STATES, 02148
UNITED STATES, Minnesota RICHFIELD, Minnesota, UNITED STATES, 55423
UNITED STATES, Nevada LAS VEGAS, Nevada, UNITED STATES, 89113
UNITED STATES, Ohio CINCINNATI, Ohio, UNITED STATES, 45236
UNITED STATES, South Carolina ANDERSON, South Carolina, UNITED STATES, 29621